Weekly News Digest: September 10, 2021
Yet another workweek is coming to an end, which means that today it’s time for the Weekly News Digest. In this edition, we’ve gathered the seven hottest news stories from the CBD and CBD-related world as of September 10, 2021. Are you ready? Let’s go!
Italian study finds CBD oral sprays can improve refractory migraine symptoms in patients
For today’s digest, we start in Italy. According to an observational study, long-term use of herbal cannabis oral preparations is associated with moderate improvements in patients with treatment-resistant migraines. The use of herbal cannabis infusions reduced the intensity of pain in patients, lessened their need for prescription analgesics, and reduced the use of prescription migraine medications. Cannabinoid tinctures also reduced the incidences of nausea and vomiting.
France launches medical cannabis pilot programme
In one of our previous digests, we told you about a medical cannabis pilot programme taking place in France. So now, medical cannabis companies have announced that the first batches of the product have been successfully shipped to France for delivery to patients participating in the country’s first pilot programme. The pilot will last about six months and will involve some 3,000 patients suffering from serious illnesses such as chronic pain and epilepsy.
CBD cancer research approved by UK National Cancer Research Institute
From continental Europe, we move on to the United Kingdom. An upcoming clinical trial examining CBD’s effects on cancer pain has been approved by the UK’s National Cancer Research Institute (NCRI). The new approval of the trial comes from the NCRI’s Living With and Beyond Cancer (LWBC) executive team. The trial will start next year, and we will monitor the situation and report back to you on the results.
New Jersey lawmakers set rules for adult-use cannabis industry
New Jersey lawmakers have passed initial rules that will lay the foundation for the state’s retail cannabis market. The New Jersey Cannabis Regulatory Commission convened to discuss and include rules that will regulate adult-use cannabis trade in the state. Under the new rules, adults aged 21 and older can buy and store up to one ounce of cannabis, but home growing will not be allowed, which is one of the main provisions that activists usually protest about. According to the new rules, gifting cannabis is allowed among adults aged 21 and older.
APAC is creating a network for cannabis prescribers
In Argentina, the Paranaense Association of Cannabis Farmers (APAC) has launched a campaign for health professionals to start working with medical cannabis. The campaign’s objective is to create a space for interdisciplinary consultations between workers from different medical fields to clear up doubts and refer users when appropriate. For its part, the group is compiling a list of professionals who perform cannabis therapies.
Israel’s Ministry of Health is close to registering over 100,000 medical cannabis patients in August
The Ministry of Health unveiled the official data on the number of medical cannabis patients in Israel for July 2021. According to the data and the growing number of people that use medical cannabis in the country, the amount should cross the 100,000 mark for the first time in August. As the official data indicates, the number of holders of a licence to use cannabis in Israel reached 99,876 patients in July, which means that it can be determined with certainty that in the current month, August, there will be over 100,000 of them.
New Zealand is introducing new quality requirements for medical cannabis products imported and traded in the country
New Zealand’s new medical cannabis rules will take effect from October 1, 2021. As of October 1, all medical cannabis products imported to or manufactured in New Zealand must be verified to meet minimum quality standards before they can be imported or supplied. The immediate result will be a sharp reduction in the range of prescription-only CBD products available, and with that, at least a twofold increase in price. For example, patients who now pay 150 New Zealand dollars (about 91 euros) for a CBD product could face a bill of nearly 241 euros for an equivalent.
We hope this coming week is as enjoyable for you as this edition of the Weekly News Digest. Have a great weekend and see you soon!